Next Article in Journal / Special Issue
ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker
Previous Article in Journal
Resolving the True Ventricular Mural Architecture
Previous Article in Special Issue
LDLR rs688 TT Genotype and T Allele Are Associated with Increased Susceptibility to Coronary Artery Disease—A Case-Control Study
Article Menu

Export Article

Open AccessFeature PaperArticle
J. Cardiovasc. Dev. Dis. 2018, 5(3), 35; https://doi.org/10.3390/jcdd5030035

Oxidized Low-Density Lipoprotein Serum Concentrations and Cardiovascular Morbidity in End Stage of Renal Disease

1
Department of Nephrology, DOCTORS’ Hospital, 26 Kefallinias, Athens 11257, Greece
2
Department of Cardiology, DOCTORS’ Hospital, Athens 11257, Greece
3
Department of Nuclear Medicine, General Hospital “LAÏKO”, Athens 11527, Greece
Running title: ox-LDL and cardiovascular disease in hemodialysis
*
Author to whom correspondence should be addressed.
Received: 21 May 2018 / Revised: 14 June 2018 / Accepted: 20 June 2018 / Published: 21 June 2018
(This article belongs to the Special Issue Lipoprotein Metabolism and Atherosclerosis)
Full-Text   |   PDF [606 KB, uploaded 21 June 2018]   |  

Abstract

Introduction: Oxidized low-density lipoprotein (ox-LDL) is considered a main biomarker of oxidative stress, a common characteristic in end stage renal disease. We examined the relationship between ox-LDL serum concentrations and cardiovascular disease in permanent hemodiafiltration therapy patients. Methods: Ox-LDL values were measured by ELISA and were corrected for LDL-cholesterol (LDL-C) in 96 participants and in 45 healthy control subjects. We performed chi-square tests and adjusted models for the role of ox-LDL on cardiovascular morbidity including coronary artery disease, left ventricular hypertrophy, systolic, diastolic dysfunction and peripheral arterial disease. Results: ox-LDL/LDL-C values were significantly higher in patients than in control group (p = 0.02), due to increased ox-LDL serum levels rather than to low LDL-C. The unadjusted relationship between high ox-LDL/LDL-C and low ejection fraction was found significant (x2 = 9.04, p = 0.003), although the association with the other cardiovascular manifestations was found non-significant. In the adjusted model for the prediction of systolic cardiac dysfunction, high ox-LDL/LDL-C, old age and non-administration of vitamin D supplementation during dialysis session were found to be significant predictors after adjustment to the confounder. Moreover, the association between systolic cardiac dysfunction and non-administration of vitamin D derivatives during dialysis sessions was found significant (x2 = 6.9, p = 0.008). Conclusions: This study showed a significant association between high ox-LDL and systolic cardiac dysfunction in permanent hemodiafiltration therapy patients. This relationship seems to be influenced by aging and pharmaceutical therapy during dialysis sessions, including vitamin D derivatives. View Full-Text
Keywords: lipoprotein oxidation; oxidative stress; hemodiafiltration; cardiovascular disease; malnutrition; vitamin D lipoprotein oxidation; oxidative stress; hemodiafiltration; cardiovascular disease; malnutrition; vitamin D
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Raikou, V.; Kardalinos, V.; Kyriaki, D. Oxidized Low-Density Lipoprotein Serum Concentrations and Cardiovascular Morbidity in End Stage of Renal Disease. J. Cardiovasc. Dev. Dis. 2018, 5, 35.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Cardiovasc. Dev. Dis. EISSN 2308-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top